HC Wainwright Reaffirms Buy Rating for Amyris (NASDAQ:AMRS) – Mitchell Messenger


HC Wainwright reaffirmed their buy rating on shares of Amyris (NASDAQ:AMRS) in a research report report published on Friday, October 11th, AnalystRatings.com reports. The firm currently has a $11.00 price objective on the biotechnology company’s stock.

Separately, BidaskClub upgraded Amyris from a sell rating to a hold rating in a research note on Tuesday, August 13th.

Shares of AMRS stock traded down $0.21 during mid-day trading on Friday, hitting $3.96. The stock had a trading volume of 394,800 shares, compared to its average volume of 1,909,886. The firm has a market capitalization of $375.34 million, a P/E ratio of -1.57 and a beta of 0.91. Amyris has a 12-month low of $1.87 and a 12-month high of $7.57. The firm’s 50-day moving average is $4.02 and its two-hundred day moving average is $3.89.

A number of large investors have recently made changes to their positions in the stock. Traynor Capital Management Inc. increased its position in Amyris by 33.3% during the 3rd quarter. Traynor Capital Management Inc. now owns 14,000 shares of the biotechnology company’s stock valued at $66,000 after buying an additional 3,500 shares in the last quarter. Rhumbline Advisers increased its position in Amyris by 8.8% during the 3rd quarter. Rhumbline Advisers now owns 54,258 shares of the biotechnology company’s stock valued at $258,000 after buying an additional 4,379 shares in the last quarter. Rice Hall James & Associates LLC increased its position in Amyris by 2.6% during the 3rd quarter. Rice Hall James & Associates LLC now owns 192,946 shares of the biotechnology company’s stock valued at $918,000 after buying an additional 4,915 shares in the last quarter. American Financial Advisors LLC increased its position in Amyris by 31.3% during the 2nd quarter. American Financial Advisors LLC now owns 21,000 shares of the biotechnology company’s stock valued at $74,000 after buying an additional 5,000 shares in the last quarter. Finally, Swiss National Bank increased its position in Amyris by 8.7% during the 2nd quarter. Swiss National Bank now owns 71,200 shares of the biotechnology company’s stock valued at $253,000 after buying an additional 5,700 shares in the last quarter. 29.41% of the stock is currently owned by institutional investors.

Amyris Company Profile

Amyris, Inc, an integrated renewable products company, delivers alternatives to petroleum, plant, and animal-based products across a range of consumer and industry segments worldwide. It applies its bioscience solutions to convert plant sugars into hydrocarbon molecules, specialty ingredients, and consumer products.

Read More: How to Use the New Google Finance Tool



Receive News & Ratings for Amyris Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Amyris and related companies with MarketBeat.com’s FREE daily email newsletter.



Source link